FindTrial
Sign In

Clinical Efficacy and Safety Analysis of paxlovid in the Treatment of Elderly sars-cov-2 Omicron infection.

Clinical Efficacy and Safety Analysis of paxlovid in the Treatment of Elderly sars-cov-2 Omicron infection.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066990
Enrollment
Unknown
Registered
2022-12-22
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sars-cov-2 Omicron infection

Interventions

paxlovid treatment group:No
control group:No

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 99 Years

Inclusion criteria

Inclusion criteria: On the basis of the Chinese guidelines for diagnosis and treatment of COVID-19, patients were diagnosed as showing laboratory-confirmed Omicron infection (SARS-CoV-2 variant) at Zhongshan Hospital MinHang MeiLong Branch, Fudan University (Shanghai, China).

Exclusion criteria

Exclusion criteria: The exclusion criteria for this study were as follows: 1. Severe hepatic and renal insufficiency; 2. Pregnant or lactating women; 3. Allergic to drugs used in this study; 4. Consuming other antiviral drugs. 5. Risk of serious adverse effects from interactions with other drugs. 6. Severe or critical pneumonia at admission.

Design outcomes

Primary

MeasureTime frame
Adverse reactions;Hospital stay;viral shedding time;changes in laboratory testing during hospitalization;changes in laboratory testing during hospitalization;—

Countries

China

Contacts

Public ContactJiang LIbo

Zhongshan Hospital, Fudan University

jiang.libo@zs-hospital.sh.cn13681903416

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026